» Authors » Dieter Vandenheuvel

Dieter Vandenheuvel

Explore the profile of Dieter Vandenheuvel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 1088
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Moretti S, Smets W, Hofman J, Mubiana K, Oerlemans E, Vandenheuvel D, et al.
Environ Pollut . 2018 Oct; 244:118-126. PMID: 30326385
Bacterial endotoxins are a component of particulate matter (PM) with anticipated health implications, yet we know little about how host reception of endotoxin through toll-like receptor 4 (TLR4) is affected...
12.
De Boeck I, Wittouck S, Wuyts S, Oerlemans E, van den Broek M, Vandenheuvel D, et al.
Front Microbiol . 2017 Dec; 8:2372. PMID: 29238339
To improve our understanding of upper respiratory tract (URT) diseases and the underlying microbial pathogenesis, a better characterization of the healthy URT microbiome is crucial. In this first large-scale study,...
13.
Vandenheuvel D, Rombouts S, Adriaenssens E
Methods Mol Biol . 2017 Nov; 1681:59-69. PMID: 29134587
In bacteriophage research and therapy, most applications ask for highly purified phage suspensions. The standard technique for this is ultracentrifugation using cesium chloride gradients. This technique is cumbersome, elaborate and...
14.
Broeckx G, Vandenheuvel D, Henkens T, Kiekens S, van den Broek M, Lebeer S, et al.
Int J Pharm . 2017 Oct; 534(1-2):35-41. PMID: 28986319
Increasing knowledge about the human microbiome has led to a growing awareness of the potential of applying probiotics to improve our health. The pharmaceutical industry shows an emerging interest in...
15.
Allonsius C, van den Broek M, De Boeck I, Kiekens S, Oerlemans E, Kiekens F, et al.
Microb Biotechnol . 2017 Aug; 10(6):1753-1763. PMID: 28772020
A number of clinical studies have shown protective effects of lactobacilli against Candida species in the gastrointestinal tract, the urogenital tract and the oral cavity, while others did not show...
16.
Roszniowski B, Latka A, Maciejewska B, Vandenheuvel D, Olszak T, Briers Y, et al.
Appl Microbiol Biotechnol . 2016 Oct; 101(3):1203-1216. PMID: 27770178
Burkholderia phage AP3 (vB_BceM_AP3) is a temperate virus of the Myoviridae and the Peduovirinae subfamily (P2likevirus genus). This phage specifically infects multidrug-resistant clinical Burkholderia cenocepacia lineage IIIA strains commonly isolated...
17.
Danis-Wlodarczyk K, Vandenheuvel D, Jang H, Briers Y, Olszak T, Arabski M, et al.
Sci Rep . 2016 Jun; 6:28115. PMID: 27301427
Bacteriophage therapy is currently resurging as a potential complement/alternative to antibiotic treatment. However, preclinical evaluation lacks streamlined approaches. We here focus on preclinical approaches which have been implemented to assess...
18.
Broeckx G, Vandenheuvel D, Claes I, Lebeer S, Kiekens F
Int J Pharm . 2016 Apr; 505(1-2):303-18. PMID: 27050865
The increasing knowledge about the human microbiome leads to the awareness of how important probiotics can be for our health. Although further substantiation is required, it appears that several pathologies...
19.
Rombouts S, Volckaert A, Venneman S, Declercq B, Vandenheuvel D, Allonsius C, et al.
Front Microbiol . 2016 Mar; 7:279. PMID: 27014204
Pseudomonas syringae pv. porri, the causative agent of bacterial blight in leek (Allium porrum), is increasingly frequent causing problems in leek cultivation. Because of the current lack of control measures,...
20.
Vandenheuvel D, Lavigne R, Brussow H
Annu Rev Virol . 2016 Mar; 2(1):599-618. PMID: 26958930
Recently, a number of phage therapy phase I and II safety trials have been concluded, showing no notable safety concerns associated with the use of phage. Though hurdles for efficient...